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ABSTRACT 
Purpose: To investigate the clinical value of 18F-Fluorocholine PET/CT (CH-
PET/CT) regarding treatment decisions in patients with recurrent prostate cancer 
(rPCA). 
Methods: Retrospective evaluation of 156 patients with rPCA and CH-PET/CT for re-
staging. Questionnaires for each examination were sent to the referring physicians 
14-64 months after examination. Questions included information regarding initial 
extent of disease, curative first-line treatment, as well as the treatment plan before 
and after CH-PET/CT. Additionally, PSA values were collected from the 
questionnaire at diagnosis, after initial treatment, before CH-PET/CT and at the end 
of follow-up. 
Results: Mean follow-up was 42 months; mean Gleason Score was 6.9 at initial 
diagnosis. Initial treatment was: Radical prostatectomy (n=110), radiotherapy (n=39), 
combined prostatectomy and radiotherapy (n=7). Median PSA values before CH-
PET/CT and at end of follow-up were 3.40 ng/ml and 0.91 ng/ml. PSA levels 
remained stable, dropped or were below measurable levels in 108 patients. PSA 
levels rose in 48 patients. In 75/156 patients (48%) treatment plan changed due to 
findings in CH-PET/CT. In 33 patients the therapeutic modality changed from a 
palliative to a curative intended treatment. In 15 patients the therapeutic modality was 
altered from a curative towards a palliative setting. 8 patients had a change from one 
curative modality to another and 2 patients from one palliative modality to another. 17 
patients had adaptations within their therapeutic modality. 
Conclusion: CH-PET/CT has an important impact on therapeutic strategy in patients 
with recurrent prostate cancer and can help to determine an appropriate treatment. 
INTRODUCTION 
Adenocarcinoma of the prostate (PCA) is the most common malignant tumor in men 
in the United States of America with second-most cancer-deaths per year following 
bronchial carcinoma [1]. Nevertheless current staging and re-staging procedures 
especially regarding nodal involvement and distant metastases still have many 
limitations leading to insufficiencies in curatively intended therapies. Consequently as 
many as 19-53 % of treated patients with initially curative intention suffer from 
recurrent disease [2-5]. Rising levels of prostate specific antigen (PSA) in the blood 
serum of patients indicate tumor progression often long before imaging modalities 
can detect any abnormalities. In this biochemical relapse situation there are no 
guidelines giving any conclusive suggestions regarding imaging procedures. Bone-
scintigraphy and CT are both insensitive and show reliable results only at PSA levels 
of above 20 ng/ml [6]. Thus according to the current guidelines these examinations 
can safely be omitted. Depending solely on the kinetics of the rising PSA levels the 
decision is made whether a local recurrence or a distant recurrence is present. If a 
local recurrence is suspected patients may qualify for a salvage procedure of the 
prostate fossa. If distant disease is suspected only palliative antihormonal treatment 
is suggested. MRI with endorectal coil shows reliable results in the evaluation of the 
prostate fossa but is not routinely recommended by the guidelines [6-8]. 18F-Choline 
PET/CT (CH-PET/CT) is a promising examination tool for the detection of recurrent 
prostate cancer (rPCA) [9]. Even though the exact role of the examination is still 
being discussed it seems that CH-PET/CT starts playing a role in the management of 
patients with a biochemical relapse [10] [11]. Several studies have demonstrated that 
CH-PET/CT either labeled with C-11 [12] [13] or with F-18 [14] [15] can detect tumor 
recurrence at PSA levels of above 2ng/ml giving the clinicians the opportunity of a 
curative intended salvage procedure at an early time-point of the recurrence [12-15]. 
In certain constellations tumor recurrence can even be detected if PSA levels are 
below the level of 2ng/ml, however the detection rates drop in these patient 
populations down to approx. 30-40% [13] [16]. Even though localized treatment of 
distant metastases currently is not an established therapy several reports have 
already been published, showing promising results regarding CH-PET/CT guided 
radiation therapy and salvage surgery [17-19]. We therefore retrospectively analyzed 
the impact of the results of CH-PET/CT examinations performed at our institution on 
treatment decisions.
MATERIALS AND METHODS  
This study was conducted according to the local-ethics committee guidelines for 
retrospective analyses. Between March 2003 and October 2007 we performed 353 
CH-PET/CT examinations in patients with PCA. Of these patients 229 had had rising 
PSA levels after an initial treatment with surgery, radiation therapy or both, indicating 
recurrent disease. Since no recommendations were given by the guidelines previous 
conventional imaging (e.g. bone-scan, MRI, CT) was not required for inclusion into 
our follow-up study [6-8]. Questionnaires were created and sent to the referring 
physicians in December 2008, 14 months after the scan of the last included patient. 
After a waiting period of approximately 4 weeks those physicians who had not 
returned the questionnaires were once reminded by telephone.  
 
CH-PET/CT 
All the data were acquired on a combined PET/CT in-line system (Discovery LS or 
Discovery ST, GE Health Systems, Milwaukee, WI). These dedicated systems 
integrate a PET scanner (GE Advance Nxi, GE Health Systems, Milwaukee, WI) with 
a multislice helical CT (LightSpeed plus or LightSpeed 16; GE Health Systems, 
Milwaukee, WI) and permit the acquisition of co-registered CT and PET images in 
one session. No oral or intravenous CT contrast agent was used. Patients were 
examined in the supine position. The unenhanced CT scans were acquired with the 
following parameters: 80 mA, 140 kV, 0.5-second tube rotation, 4.25 mm section 
thickness, 867 mm scan length, and 22.5 second data acquisition time. The CT 
scans were acquired during breath hold with the normal expiration position, and 
scanning included the area from the head to the pelvic floor. The PET emission scan 
started 3-4 minutes after the injection of a standard dose of 200-300 MBq 18F-
Fluorocholine. After the acquisition of a partial-body scan (pelvic floor to vertex) 
approx. 15-20 min post-injection a second partial-body scan with same scan-length 
was acquired, without taking the patient off the examination-table and without voiding 
of the bladder. The PET images were acquired starting at the level of the pelvis, with 
an acquisition time of 3 minutes for the emission scan per cradle position and a one-
slice overlap. The CT data were used for attenuation correction, and images were 
reconstructed using a standard 2D-iterative algorithm (ordered subset expectation 
maximization). 
For image fusion, 4.25 mm thick CT image-slices were reconstructed. Images were 
then transferred to a commercially available workstation (GE Advantage 
Workstation). These workstations allow simultaneous data evaluation of early and 
late phase PET studies with the corespondig CT images as a single procedure and in 
an image fusion mode. 
Both partial-body PET scans were fused with the CT-scan and read side by side. The 
early scan was primarily used for the evaluation of the prostate fossa because at this 
time the tracer hasn’t arrived in the bladder. The late scan was used for better 
differentiation between reactive / Inflammatory and malignant lymph nodes [20]. A 
visually detectable washout of the tracer from lymph nodes over time was considered 
as benign whereas a persisting or increasing tracer-activity in lymph nodes was 
considered as a sign for malignancy. 
 
Diagnostic Findings 
All CH-PET/CT examinations were reported by a dual-board-certified radiologist / 
nuclear medicine physician with 5 years of experience in CH-PET/CT reading. The 
findings from each CH-PET/CT examination were collected from these written 
reports. Although performed in some patients a validation of the findings from CH-
PET/CT with other imaging methods or with a histological workup could not be 
obtained consistently due to the retrospective character of the study and was 
therefore not required for inclusion into the study-population. 
 
Questionnaire: 
The questionnaire consisted of questions regarding the following topics: 
1) Initial TNM – stage and initial grading according to Gleason 
2) Initial therapies and antihormonal treatments 
3) Treatment after CH-PET/CT and hypothetical treatment if no CH-PET/CT had 
been available. 
4) PSA values at diagnosis, after initial therapy, before CH-PET/CT and at the 
end of follow-up. 
The referring physicians had to indicate the therapeutic strategy of the patient as it 
had been defined after the results from CH-PET/CT. Then they had to define a 
hypothetical therapeutic strategy, assuming the results from the CH-PET/CT had not 
been available. Additionally they had to indicate whether the effectively chosen 
treatment plan had been influenced by the CH-PET/CT (Table 2).  A change in 
therapy consisted of the choice of a different therapeutic modality (e.g. antihormonal 
therapy à radiation therapy) or of an alteration within a therapeutic modality (e.g. 
adaptation of the radiation field) 
 
Statistical data analysis: 
General descriptive statistics were performed to calculate mean age, mean follow-up 
and median PSA-values. Due to the substantial skew of the PSA value distribution a 
logarithmic transformation was performed for all PSA values to obtain a symmetric 
distribution. A constant value of 0.01 was added to all PSA values before 
transformation to make PSA values of zero valid for transformation. PSA 
development-ratios from PSA values before and after CH-PET/CT were calculated by 
subtracting the log transformed post-CH-PET/CT values from the log transformed 
pre-CH-PET/CT values. Non-parametric testing (Mann-Whitney U Test) was used for 
comparison of PSA development-ratios among different patient subgroups. The 
Wilcoxon signed rank test was used for comparison of PSA values before and after 
CH-PET/CT. P-values < 0.05 were considered significant. All statistical analyses 
were performed using SPSS for Windows, Release 18.0.0 (SPSS Inc., Chicago, IL) 
 RESULTS 
Disease characteristics 
A total of 163 questionnaires could be obtained by the referring physicians. 7 patients 
with returned questionnaires had to be excluded because of missing PSA values 
before CH-PET/CT and/or at the end of follow-up. Finally 156/229 (68%) completed 
questionnaires could be used for evaluation (Table 1). Mean follow-up was 42 
months (range 14 – 64 months). Mean age of the patients at the time of CH-PET/CT 
was 66 years (range 48 – 81 years). At diagnosis the mostly represented tumor stage 
was T3 N0 M0 with a mean Gleason Score of 6.91 (Table 2). Initial treatment 
consisted of radical prostatectomy in 110 patients. 39 patients had undergone 
radiotherapy and 7 patients a combination of both.  
 
Diagnostic performance 
Positive findings in CH-PET/CT were reported in 124/156 (79%) patients. 63/156 
(40%) patients had a local recurrence only, 27/156 (17%) patients had lymphatic 
metastases only and 9/156 (6%) patients had metastases to the bones only. A local 
recurrence plus nodal metastases were found in 14/156 (8%) patients and 8/156 
(5%) of patients had local recurrence plus bony metastases. 4/156 (3%) of patients 
had tumor manifestations in the prostate fossa, in lymph nodes and in the bones. 
 
Effective vs. hypothetical treatment 
In 75/156 patients (48%) the referring physicians indicated a change of the 
therapeutic strategy. In 33 patients (21%) the therapeutic modality changed from a 
palliative to a curative intended treatment (surgery, radiation therapy, HIFU and 
combined therapies). In 15 patients (10%) the therapeutic modality was altered from 
a curative towards a palliative setting (watchful waiting, antihormonal treatment or 
chemotherapy).  8 patients (5%) had a change from one curative modality to another 
and 2 patients (1%) from one palliative modality to another. 17 patients (11%) had 
adaptations within their therapeutic modality (Tables 2 and 3). In 8 patients (6%) a 
change in therapy was indicated even though CH-PET/CT showed no abnormities. 
Three of these patients (initially operated) scheduled for RT before CH-PET/CT had 
an adaptation of their radiation field. One patient (initially operated) was changed 
from RT to surgery. One patient (initially operated) scheduled for surgery had an 
adaptation of his surgical procedure. One patient (initially operated) scheduled for RT 
and additional antihormonal treatment was changed to antihormonal treatment only. 
One patient (initially with RT) was changed from antihormonal treatment to watchful 
waiting. One patient (initially operated) scheduled for antihormonal treatment had an 
adaptation of this treatment.  
 
PSA values 
Table 4 summarizes the PSA values of our patient population at the different time-
points. Since 2 patients had extraordinarily high PSA values at the end of follow-up 
(One patient had a PSA of 150 ng/ml and the other 334.8 ng/ml) not only mean PSA 
levels but also median values were calculated to correct for the overwhelming 
influence of these two patients on the results. PSA levels before CH-PET/CT were 
significantly higher compared to those at the end of follow-up (P < 0.001; Wilcoxon 
signed rank test). At the end of follow-up, PSA values declined in 107 patients (69%) 
due to subsequent therapies. Of these 107 patients 16 (10%) had values below the 
measurable threshold. 1 patient (1%) had a stable PSA and in 48 patients (31%) the 
PSA levels increased.  
PSA values before CH-PET/CT were significantly higher (P < 0.001, Mann-Whitney U 
Test) in patients with positive CH-PET/CT scans (median PSA 4.50 ng/ml, range 0.15 
- 296.61 ng/ml) compared to those with negative scans (median PSA 1.20 ng/ml, 
range 0.1 - 30.3 ng/ml). However there was no significant difference regarding the 
PSA development-ratios (obtained from the PSA-values before and after CH-
PET/CT) in the comparison of patients with positive CH-PET/CT to those with 
negative scans (P = 0.70, Mann-Whitney U Test). These two groups did not differ 
regarding initial PSA levels at the time point of diagnosis (P = 0.48, Mann-Whitney U 
Test). 
PSA values of the patients where the intended treatment plan was changed after CH-
PET/CT (n=75, 48%) were compared with those of patients where no change of 
treatment had been performed (n=81, 52%). There was no significant difference 
between these two groups regarding the PSA development-ratios (pre-/post CH-
PET/CT) (P = 0.68, Mann-Whitney U Test).  Again the PSA values at the time of 
primary diagnosis were not significantly different in these two groups (P = 0.67, 
Mann-Whitney U Test) 
DISCUSSION 
To our knowledge this retrospective analysis is the first, to analyze the clinical impact 
of CH-PET/CT on treatment decisions in patients with recurrent prostate cancer. We 
obtained our data using questionnaires, which were sent to those physicians who 
had referred their patients for a CH-PET/CT to our institution. The referring 
physicians had to provide information about the therapy, which had been performed 
after CH-PET/CT and had to determine a hypothetical therapeutic management 
without the information obtained from the CH-PET/CT. With this method we could 
demonstrate a strong clinical impact of CH-PET/CT. The results of our examination 
lead to changes of the therapy in 48% of patients, which consisted of adaptation of 
the current treatment-regime or even complete change of the therapeutic approach.  
Even though a comparison with a non-CH-PET/CT control group was not possible 
due to the retrospective study design, the performed therapies after CH-PET/CT 
were effective since a significant decline of the mean PSA values after the 
examination compared to before could be observed.  
Interestingly PSA development-ratios of patients with positive findings in CH-PET/CT 
compared to those with negative findings demonstrated no statistical significance. 
The same accounted for the comparison of patients with therapeutic changes due to 
CH-PET/CT compared to those without. We believe that there are several factors, 
which lead to these results:  
If patients had no findings in CH-PET/CT the treatment in general followed the 
standard procedures for recurrent disease [6-8]. According to the guidelines in such a 
situation if no other findings are present the decision whether a local or distant 
recurrence is present is made by the PSA kinetics. The standard procedures then are 
radiation therapy (if initially undergone surgery), antihormonal treatment, salvage 
resection, or combined approaches. After such a procedure the likelihood of a 
successful treatment is high, especially since CH-PET/CT (even though per definition 
false negative due to rising PSA) has excluded gross metastatic spread. Thus it is not 
surprising that not only those of our patients with positive findings in CH-PET/CT had 
favourable PSA development-ratios but also those without detectable pathologies in 
the CH-PET/CT examination.  
The situation with the subgroup of patients with therapeutic changes compared to 
those without is quite similar. If CH-PET/CT confirmed the suspected localization of 
recurrent disease no change of therapy management occurred. The intended 
treatment-approach remained correctly unchanged for these patients and the PSA 
development-ratios were of course as favourable as they were for those patients 
where CH-PET/CT demonstrated findings which led to a change of the therapeutic 
management.  
Therefore, it becomes clear that with our study setup it is not possible to make 
statements about the influence of CH-PET/CT on the outcome of recurrent prostate 
cancer. 
Interestingly in 8 patients the referring physicians indicated changes in therapy even 
though CH-PET/CT demonstrated no positive findings. These results can be 
explained by the fact that despite the failure to detect the recurrent disease CH-
PET/CT was able to exclude gross metastatic spread. This obviously led to changes 
of the planned treatment such as adaptation of the radiation field. 
The major limitation of our study is its retrospective character. Our referring 
physicians had to retrospectively determine which therapy would have been 
performed if no CH-PET/CT had been available. There is potential bias, since the 
referring physicians were most likely to support CH-PET/CT. Thus more favourable 
results regarding therapeutic changes could be assumed compared to a real 
prospective study design. Nevertheless we believe that no serious bias has been 
introduced into our study. First of all, according to the guidelines for prostate cancer 
recurrence the therapeutic options are not very wide. They consist of radiation 
therapy, antihormonal treatment, salvage surgery, chemotherapy or a combination of 
these. There were two categories of patients referred for CH-PET/CT. The first 
category consisted of patients who had had a complete treatment with initial curative 
therapy, recurrence, salvage procedure and again rising PSA levels. Following the 
guidelines in such a situation without further diagnostics only a palliative procedure 
with antihormonal treatment or watchful-waiting was advised. Any therapy aside 
these two options was therefore very likely to be due to CH-PET/CT and a bias was 
basically only possible if a change of therapy occurred within the two palliative 
options, which was indicated in only 2/75 patients. The second category were 
patients whose PSA didn’t decline sufficiently or started rising again after initial 
curative therapy. For these potentially curable patients the standard procedure 
according to the guidelines is a salvage locoregional therapy mostly consisting of 
surgery or radiation therapy. Thus indicated therapeutic changes from a curative to a 
palliative setting (15/75 patients) or within the same curative modality, like extended 
lymphadenectomy or extended radiation field (16/75 patients), were most likely 
correct and not due to a bias. The only potential for biasing was given in those 
patients where therapeutic changes were indicated from one curative setting to 
another (8/75 patients).   
 Conclusion 
According to the results in our patient population CH-PET/CT in patients with 
recurrent prostate cancer has an important impact on the therapeutic strategy and 
can help to determine an appropriate treatment for these patients.  
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TABLES 
Table 1 
 
 Table 1 describes our patient inclusion-pathway. 
 
353 PCA-patients CH-PET/CT 
between March 2003 - October 
2007  
229 patients rPCA with rising 
PSA after surgery and/or 
radiation therapy 
Questionnaires to referring 
physicians 14-64 months after 
examination  
Questionnaires returned by 
referring physicians: 163 patients 
Questionnaires  without missing 
relevant data: 156 patients 
Table 2 
Table 2A 
n=1; (1%)
n=2; (1%)
n=8; (5%)
n=38; (23%)
n=52; (32%)
n=27; (17%)
n=17; (10%)
n=1; (1%)
n=12; (7%)
n=5; (3%)
Gleason 2
Gleason 3
Gleason 4
Gleason 5
Gleason 6
Gleason 7
Gleason 8
Gleason 9
Gleason 10
Gleason x
 
 Table 2B 
     
 TNM-Stage N0 N1 Nx M1 
T1 14 0 0 0 
T2 52 5 6 0 
T3 61 6 6 3 
T4 2 2 1 2 
TX 0 0 1 0 
 
 
Table 2 shows the disease characteristics of our patient population. In table 2A the 
distribution of Gleason Scores is visualized. Table 2B shows the TNM stages of our 
patients. For an easier understanding patients with MX were treated as M0 in this 
table.  5 patients had distant metastases (3 patients T3 N1 M1; 1 patient T4 N0 M1 
and 1 patient T4 NX M1).. 
 Table 3 
  Watchful 
waiting 
(no 
therapy)  
Antihormonal 
treatment 
Radiation 
therapy 
Surgery HIFU Chemotherapy Anthormonal 
and 
radiation 
therapy 
Surgery 
and 
radiation 
therapy 
Therapy 
with CH-
PET/CT 
19 37 59 11 6 1 22 1 
Hypothetical 
therapy 
without CH-
PET/CT 
22 54 60 4 2 0 14 0 
 
Table 3 shows the effectively performed treatments with CH-PET/CT in the upper 
column and the hypothetical treatments without CH-PET/CT as indicated by the 
referring physicians in the lower column.  
 Table 4 
PSA At diagnosis 
Nadir after 
treatment 
Before CH-
PET/CT 
At end of follow-
up 
Available in n= 149/156 139/156 156/156 156/156 
Mean value ng/ml 22.18 0.72 9.46 9.50 
Median value 
ng/ml 12.00 0.10 3.40 0.91 
 
Table 4 describes the PSA values of our patients (including the availiability of the 
measurements) at selected time-points.
FIGURES 
Figure 1 
53 year old patient, 6 years after surgery. Rising PSA 3.0 ng/ml. Bone scintigraphy 
including SPECT/CT was read as negative, also in the right iliac bone (arrow) (1A). 
Thus a local recurrence was suspected leading to a hypothetical treatment with 
radiation therapy of the small pelvis. CH-PET/CT performed 4 weeks later revealed a 
metastasis in the iliac bone (1B). The therapy-management was changed to a 
radiation therapy of the iliac bone and additional antihormonal treatment. PSA 
declined to 2.45ng/ml 
 
 
 
Figure 2 
74 year-old patient, 3 years after surgery. Rising PSA 2.2 ng/ml. CH-PET/CT 
confirmed a clinically suspected local recurrence. No change in therapy-
management. Patient received radiation therapy and PSA declined to 0.43 ng/ml  
 
 
